Bionano Genomics Stock: What Exactly Do They Do?

Technological innovation comes and goes constantly. Retail investors should only concern themselves with technology that generates revenue. That’s when something moves from “emerging” to “disruptive.” The time for teams-with-dreams to show traction should be far behind them when they look to the public markets for capital. Special purpose acquisition companies (SPACs) changed that by normalizing the idea of funding a company that hasn’t shown revenue traction. If you’re a firm that’s disrupting something, revenue growth is not optional.

Our recent article on Pacific Biosciences (PACB) offered up a good example of a technology that appears to be – at least based on the last four quarters – breaking out. That is, revenue growth appears to have started a trajectory that implies widespread adoption. As investors, we’re always left wondering whether these revenue breakouts are temporary or permanent. For example, here’s a look at quarterly revenues for Bionano Genomics (BNGO).

Last quarter BNGO saw record revenues making us wonder if this company is finally going to see some sustained revenue growth. Bu